- Home
- » Tags
- » Lumretuzumab
Top View
- A Phase Ib/II Study of HER3-Targeting Lumretuzumab in Combination
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- Paper Jugat Pel Receptor Erbb-3 (Her-3) En El Desenvolupament I Tractament Del Càncer
- In Vivo Evaluation of a Novel Format of a Bivalent HER3-Targeting And
- PET Imaging of Receptor Tyrosine Kinases in Cancer Weijun Wei1,2,Dalongni2, Emily B
- Pdf/2009-10/Firmagon - Ct-6725.Pdf 58
- Supplemental Table 1. 89Zr-Labeled Biopharmaceuticals in Completed Or Ongoing Clinical Trials
- Gm, Ke, Lr, Ls, Mw, Mz, Na, Rw, Sd, Sl, St, Sz, Tz, Ug, Zm, Zw
- The Navigating and De-Risking Role of 89Zr-Immuno-PET in the Development of Biopharmaceuticals
- QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
- (INN) for Biological and Biotechnological Substances
- Organizational Antecedents to the Implementation of Precision Medicine: Overcoming Resistance to Change
- Anti‑HER3 Monoclonal Antibody Exerts Antitumor Activity in a Mouse Model of Colorectal Adenocarcinoma
- And Bivalent Affibody-Based Fusion Proteins Targeting HER3 In
- Methodology Results Background
- W O 2017/160990 A1 21 September 2017 (21.09.2017) W I PO I P C T
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri